Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...
Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...
Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...
Les résultats du troisième trimestre 2024 seront commentés par le management au cours d'un webcast audio en direct avec la communauté financière. La présentation sera suivie d'une session de questions ...
Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois CP : Le tolebrutinib a permis d’allonger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback